Related Experiment Videos
Cardiovascular effects of Org 9487 under isoflurane anaesthesia in man
1Department of Anaesthesiology, Justus-Liebig-University, Giessen, Germany.
Insights
Org 9487, a neuromuscular blocker, showed dose-dependent cardiovascular effects during isoflurane anesthesia. Higher doses increased heart rate and decreased blood pressure, with most effects resolving quickly.
Area of Science:
- Anesthesiology
- Pharmacology
- Cardiovascular Research
Background:
- Isoflurane anesthesia is commonly used.
- Neuromuscular blocking agents are essential in anesthesia.
- Understanding drug interactions and effects is crucial for patient safety.
Purpose of the Study:
- To evaluate the cardiovascular effects of Org 9487.
- To assess the impact of different doses of Org 9487 during isoflurane anesthesia.
- To determine the safety profile of Org 9487 in this context.
Main Methods:
- Cardiovascular parameters were monitored in patients receiving isoflurane anesthesia.
- Three doses of Org 9487 (1 mg kg-1, 2 mg kg-1, 3 mg kg-1) were administered, targeting the ED90 for neuromuscular blockade.
- Heart rate, systolic blood pressure, and diastolic blood pressure were measured.
Main Results:
- Heart rate increased with increasing doses of Org 9487.
- Significant decreases in systolic and diastolic blood pressure were observed at the highest dose (3 mg kg-1).
- Transient increases in airway pressure occurred in some patients, with transient oxygen desaturation in two cases, but were self-limiting.
Conclusions:
- Org 9487 demonstrates dose-dependent cardiovascular effects during isoflurane anesthesia.
- The highest dose tested (3 mg kg-1) caused significant hypotension.
- Org 9487 appears to be generally well-tolerated, with transient and self-limiting adverse events.
Abstract:
The cardiovascular effects of Org 9487 during isoflurane anaesthesia have been evaluated using three doses around its ED90 for neuromuscular blockade, i.e. 1 mg kg-1, 2 mg kg-1 and 3 mg kg-1. Heart rate increased to 110%, 115% and 118% in patients receiving 1 mg kg-1, 2 mg kg-1 and 3 mg kg-1 respectively. There were no significant effects on systolic and diastolic blood pressures for the two lower dose groups. Patients receiving Org 9487 3 mg kg-1 displayed significant decreases in systolic and diastolic blood pressures (91% and 82% of the control values respectively). Except for heart rate in the group receiving 3 mg kg-1, all measurements returned to baseline after a maximum of 15 min. Six patients experienced a transient increase in airway pressure after administration of Org 9487, which was accompanied by a decrease in oxygen saturation in two out of six subjects, but there was no audible wheezing. These episodes were self-limiting and required no treatment. There were no other adverse reactions to this drug during this study.